AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03650764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available
Study NCT03650764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EORTC QLQ-30
Description: -Screening, start of cycle 2, start of cycle 5
Study NCT03650764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT H&N
Description: -Screening, start of cycle 2, start of cycle 5
Study NCT03650764 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood
Description: -Baseline
Study NCT04422899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIV007
Description: intravitreal
Study NCT01160185 — intervention group
Intervention type: DRUG
Intervention: paclitaxel
Description: paclitacel
Study NCT01160185 — intervention group
Intervention type: DRUG
Intervention: cisplatin
Description: cisplatin monotherapy
Study NCT00369668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral movements and neuromuscular electrical stimulation
Description: Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
Study NCT00369668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral movements and sham electrical stimulation
Description: Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
Study NCT03415919 — intervention group
Intervention type: OTHER
Intervention: no intervention will be given to patients.
Description: samples are collected at the time of a scheduled procedure that is part of normal treatment. This study will not have any impact on the care or treatment the patient receives.
Study NCT01160185 — intervention group
Intervention type: DRUG
Intervention: topotecan
Description: topotecan
Study NCT02502552 — intervention group
Intervention type: OTHER
Intervention: blood specimen
Description: blood specimen
Study NCT02075060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IPOI (pre-operative)
Study NCT02075060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPOP (post-operative)
Study NCT03616340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shoulder injection
Description: intra articular or subacromial shoulder injection
Study NCT03616340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: knee injection
Description: intra-articular knee injection
Study NCT01342055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apetrol ES
Description: sequences of administered drugs
Study NCT03436446 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Interviews will be conducted with orthopedic patients to review the construction and phrasing of various social incentives aimed at promoting patient reported outcome collection amongst post-operative patients.
Study NCT03430687 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03430687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given intravesically
Study NCT03212404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CK-301 (cosibelimab)
Description: CK-301 will be administered in periods of 28-day cycles.
Study NCT02335216 — intervention group
Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study NCT01487668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care
Description: LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
Study NCT03649100 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant placement
Description: Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
Study NCT03649100 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Conventional implant placement. Implant site development was prepared according to the manufacturer's instruction by the investigator, before knowing the randomized implant (NH or SA).
Study NCT02083510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Study NCT01401010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doripenem
Description: 500 mg every 8 hours
Study NCT01401010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doripenem
Description: 1000 mg every 8 hours
Study NCT04604106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Eyetracker
Description: Eye-tracking is an objective, non-invasive method and particularly suited to assess neurodevelopmental outcome in infants.
Study NCT04604106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ages & Stages questionnaire
Description: The Ages \& Stages Questionnaire is a conventional instrument used to measure developmental outcome in infants.
Study NCT04604106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bayley Scale of Infant Development
Description: The Bayley Scale of Infant Development is a conventional instrument used to measure developmental outcome in infants.
Study NCT03289403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunomodulatory
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:~1. Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued~2. Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.~3. Immunoglobulins will be used in cases not responding to treatment.
Study NCT03289403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thyroxine
Description: Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.~Patients will not receive immunomodulatory drugs
Study NCT03375242 — intervention group
Intervention type: DRUG
Intervention: crizotinib
Description: XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status.
Study NCT03148002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Current Bowel Protocol (senna/lactulose)
Description: Stimulant and Osmotic Laxatives.
Study NCT03148002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG Bowel Protocol (PEG/lactulose)
Description: Osmotic Laxatives.
Study NCT03828604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress; Trier Social Stress Task
Description: Standardized acute psychosocial stressor
Study NCT03828604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Trier Social Stress Task
Description: Active control version of the TSST
Study NCT04489797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Participants will receive single oral dose of acalabrutinib on day 1 as per the arms they are randomized.
Study NCT04489797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Participants will receive twice daily oral dose of 20 mg rabeprazole on days -3, -2, and -1.
Study NCT01315665 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli sprouts
Description: Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
Study NCT01431989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL
Description: Test formulation
Study NCT01431989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxil® 500mg/5mL powder for oral suspension
Description: Reference formulation
Study NCT00091442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
Study NCT00091442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
Study NCT00091442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Study NCT03847246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baraclude® tablets,1.0 mg
Description: oral,once,under fasting condition
Study NCT03847246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir tablets,1.0 mg
Description: oral,once,under fasting condition
Study NCT00581243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLV-313 SR
Description: sustained relase tablets taken once daily for 14 days
Study NCT03605589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous IV infusion
Study NCT03605589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03417219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and Skill Building Rehabilitation-mobile (ESBR-m)
Description: Participants randomized to the ESBR-m group will participate in four, 90-minute group ( 5 participants) sessions. These four sessions are supplemented with a booster session one month following the last intervention session.
Study NCT03417219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Participants randomized to the UC group will receive supplemental educational materials (e.g., VA Caregiver Support Program; Veterans Crisis Line; National Institute on Aging's Understanding Memory Loss).
Study NCT02699814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H3 Services
Description: A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
Study NCT03345914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Solution for injection in pre-filled syringe;~Route of administration: Subcutaneous (SC)
Study NCT03345914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo
Description: Pharmaceutical form: Solution for injection;~Route of administration: Subcutaneous (SC)
Study NCT03345914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Background Treatment: Topical Corticosteroids
Description: All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
Study NCT00629603 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytokine
Description: polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
Study NCT00629603 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytokine polymorphisms
Description: Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
Study NCT00629603 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: cytokine polymorphism
Description: fibrosis-relating cytokine polymorphism
Study NCT04446052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GM-CSF priming
Study NCT04446052 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00925275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I-131-CLR1404
Description: Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
Study NCT03840967 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Niraparib
Description: Niraparib will be administered as a flat-fixed daily dose depending on weight and platelet count. Subjects will take orally on a daily basis for 28 days. Each cycle = 28 days
Study NCT04809337 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: After manuel therapy, the patients were allocated into two groups as Stabilization Exercise Group and Therapeutic Exercise Group randomly.
Study NCT02400684 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood samples
Description: Evolution of AMH before and after deep endometriosis surgery
Study NCT00836706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: 500 mg Tablet
Study NCT00836706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAXIN®
Description: 500 mg Tablet
Study NCT04150718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: slow-wave disruption
Description: A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
Study NCT04150718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: slow-wave disruption
Description: A tone will be played through a speaker mounted over the bed that disrupts subjects while they are in slow-wave sleep. The tone will not be loud enough to wake up.
Study NCT03058952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
Study NCT03058952 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program
Description: The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
Study NCT04539171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education and Physical Exercise
Description: Patients assigned to the experimental group perform a PNE program consisting of seven sessions, with therapeutic PE. PNE is a health education intervention aims to provide up-to-date information on neuroscience advances in the field of chronic pain.
Study NCT01168596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Comparison of Rasagiline versus placebo.~Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks.
Study NCT01168596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
Study NCT01156844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
Study NCT01156844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Indacaterol
Description: Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
Study NCT01156844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Indacaterol
Description: Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
Study NCT04746755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Lower Back
Description: This Insole is a full-length shaped orthotic insole, with a heel cup and an arch support. The insole can cover several shoe sizes and can be cut to the correct size to fit in the shoe.
Study NCT04746755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Heel
Description: This Insole is a horseshoe shaped flexible heel cup with a softer area where the heel would be expected.
Study NCT04746755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Knee to Heel
Description: This Insole is a ¾ length rigid orthotic insole with a softer area where the heel would be expected. Each insole will cover several shoe sizes.
Study NCT04746755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthotic Insole: Arch
Description: This Insole is a ¾ length shaped medical device with a softer area incorporated into the ball of foot and heel area and an external arch.~support and 6-8 mm metatarsal dome. The slim fit insole runs from the heel along under the arch of the foot and reaches to just behind the toes to prevent squashing the toes in tight fitting shoes.
Study NCT04608708 — intervention group
Intervention type: OTHER
Intervention: The data of patients who had applied to the clinic for various reasons and were diagnosed with fibro-osseous lesions
Description: lesions diagnosed radiologically and followed up for at least one year were included in this study with the help of cone beam computed tomography.
Study NCT03022721 — intervention group
Intervention type: OTHER
Intervention: No interventions are planned for this study.
Description: No interventions are planned for this study, it is purely observational.
Study NCT00337168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Description: Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
Study NCT00337168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
Study NCT00615888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast track patient management
Description: no bowel washout, patient controlled epidural anesthesia, early enteral feeding
Study NCT00615888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional management
Description: preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
Study NCT01235949 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose
Study NCT01235949 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix-IPV/Hib
Description: Intramuscular injection, 1 dose
Study NCT03929588 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held device supported by a mobile application
Description: Hand-held device supported by a mobile application to obtain refractive error of the eye.
Study NCT03929588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoropter
Description: Manual refraction and ETDRS chart
Study NCT03929588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autorefractor
Description: Automated refraction
Study NCT04956822 — intervention group
Intervention type: OTHER
Intervention: Basic information
Description: Demographic data registration, medical history taking, physical examination. Electrocardiogram. Pulmonary function tests.
Study NCT02323048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methamphetamine
Description: : Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
Study NCT02323048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo (sugar pill)
Study NCT00212004 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Study NCT00212004 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Study NCT01999530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin Hydrochloride
Description: Gradual upward titration to 15mg/day for approximately three weeks.
Study NCT02014467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Injection